Acceso abierto

Designing ATHN 7: Safety, effectiveness and practice of treatment of people with haemophilia in the United States through a natural history cohort study

Tyler W. Buckner

Tyler W. Buckner

Hemophilia and Thrombosis Center, University of Colorado School of MedicineAurora, United States
Perfil de Orcid
Buscar este autor en
Sciendo|Google Scholar
Buckner, Tyler W.
, 
Nabil Daoud

Nabil Daoud

American Thrombosis and Hemostasis NetworkRochester, United States
Buscar este autor en
Sciendo|Google Scholar
Daoud, Nabil
, 
Moses Miles

Moses Miles

American Thrombosis and Hemostasis NetworkRochester, United States
Buscar este autor en
Sciendo|Google Scholar
Miles, Moses
, 
Carrie O'Neill

Carrie O'Neill

American Thrombosis and Hemostasis NetworkRochester, United States
Buscar este autor en
Sciendo|Google Scholar
O'Neill, Carrie
, 
Crystal Watson

Crystal Watson

American Thrombosis and Hemostasis NetworkRochester, United States
Buscar este autor en
Sciendo|Google Scholar
Watson, Crystal
 y 
Michael Recht

Michael Recht

American Thrombosis and Hemostasis NetworkRochester, United States
Perfil de Orcid
Buscar este autor en
Sciendo|Google Scholar
Recht, Michael
  
03 ene 2023
Designing ATHN 7: Safety, effectiveness and practice of treatment of people with haemophilia in the United States through a natural history cohort study's Cover Image
Acerca de este artículo
Artículo anterior
Artículo siguiente
Cite
Descargar portada
Categoría del artículo: Clinical Research
Publicado en línea: 03 ene 2023
Páginas: 147 - 155
DOI: https://doi.org/10.2478/jhp-2022-0020
Palabras clave
© 2022 Tyler W. Buckner et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
The American Thrombosis and Hemostasis Network (ATHN) is building a comprehensive dataset on treatment safety, effectiveness, regimens, target joints, and patient-reported outcomes for people with haemophilia in the United States
The American Thrombosis and Hemostasis Network (ATHN) is building a comprehensive dataset on treatment safety, effectiveness, regimens, target joints, and patient-reported outcomes for people with haemophilia in the United States

Figure 1

ATHN 7 schedule of eventsAE: Adverse event PRO: Patient-reported outcome
ATHN 7 schedule of eventsAE: Adverse event PRO: Patient-reported outcome

Figure 2

ATNH 7 accrualActual versus projected accrual into ATHN 7. The shaded area represents the onset of the COVID-19 pandemic and the decision to pause accrual into ATHN 7 with the planned transition of participants into ATHN Transcends.
ATNH 7 accrualActual versus projected accrual into ATHN 7. The shaded area represents the onset of the COVID-19 pandemic and the decision to pause accrual into ATHN 7 with the planned transition of participants into ATHN Transcends.

Figure 3

List of participating HTCs and accruals by site
List of participating HTCs and accruals by site

Patient-reported outcomes data collected from participants (or parent proxies) at enrolment in ATHN 7

AGE OF PARTICIPANT (YEARS) 0–4 5–7 8–11 12–17 >18
EQ-5D-5L X X
PROMIS-29 X
PROMIS-25 X X
PROMIS-25 parent proxy X
GAR X X
GAR parent proxy X X X
Idioma:
Inglés
Calendario de la edición:
1 veces al año
Temas de la revista:
Medicina, Ciencias médicas básicas, Ciencias médicas básicas, otros, Medicina Clínica, Medicina Clínica, otros, Farmacia, Farmacología
RSS Feed de revista